Why Exelixis Stock Trounced the Market on Thursday
Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a ...
BP’s CEO Cut His Teeth on Crisis — Now He Faces the Toughest Test Yet
“Boy, his hat is crises!” said Bob Dudley, former BP CEO and a mentor to Auchincloss. “I always said to Murray: management ...
Le Lézard2d
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
Exelixis, Inc. today announced that the company's Board of Directors has authorized the repurchase of up to an additional $500 million of the company's common stock before December 31, 2025. Exelixis ...
Barclays Sticks to Its Hold Rating for Exelixis (EXEL)
In a report released today, Peter Lawson from Barclays maintained a Hold rating on Exelixis (EXEL – Research Report), with a price target of ...